Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish Sells 27,453 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 27,453 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total value of $315,434.97. Following the transaction, the chief operating officer now owns 867,677 shares in the company, valued at $9,969,608.73. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $11.36 on Friday. The company has a market capitalization of $1.61 billion, a PE ratio of -8.88 and a beta of 1.43. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The stock’s 50 day moving average price is $10.26 and its 200-day moving average price is $8.13. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $17.34.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. R Squared Ltd bought a new stake in shares of Alphatec during the 4th quarter worth $29,000. Nisa Investment Advisors LLC increased its holdings in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after buying an additional 4,234 shares during the last quarter. Newton One Investments LLC bought a new stake in Alphatec in the fourth quarter worth about $50,000. XTX Topco Ltd purchased a new position in Alphatec in the third quarter valued at about $69,000. Finally, Net Worth Advisory Group bought a new position in shares of Alphatec during the 3rd quarter valued at approximately $76,000. Institutional investors own 66.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Barclays lifted their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a report on Tuesday, January 14th. Finally, Needham & Company LLC upped their target price on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.